Where on the Healthcare Continuum Should We Invest? The Case for Primary Care?

References 

1. Begg SJ, Vos T, Barker B, Stanley L, Lopez AD. Burden of disease and injury in Australia in the new millennium: measuring health loss from diseases, injuries and risk factors. Med J Aust. 2008;188:36–40
2. Australian Institute of Health and Welfare. Health expenditure Australia 2006-07. Health and welfare expenditure series no. 35. Cat. no. HWE 42. Canberra: AIHW, 2008 (available at http://www.aihw.gov.au/publications/hwe/hea06-07/hea06-07.pdf; accessed December 2008).
3. Productivity Commission. Economic implications of an ageing Australia, research report. Canberra: Productivity Commission, 2005 (available at http://www.pc.gov.au/projects/study/ageing/docs/finalreport; accessed December 2008).
4. Bennett C. Beyond the blame game. Med J Aust. 2008;189:31–32
5. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, et al. Explaining the decrease in U.S. deaths from coronary disease 1980–2000. N Engl J Med. 2007;356:2388–2398
   • CrossRef
6. The shifting burden of cardiovascular disease in Australia. Report by Access Economics Pty. Ltd for the National Heart Foundation of Australia; 2005.
7. Tonkin AM. Future challenges. In:  Tonkin AM editors. Atherosclerosis and heart disease. London: Martin Dunitz; 2003;
8. Peeters A, Nusselder W, McNeil J, Moon L, Boyko E, Tonkin A. Age-specific trends in cardiovascular mortality rates in Australia, the Netherlands and USA since 1980. In: Abstract presented to European Congress of Cardiology. 2008;
9. Manuel DG, Lim J, Tanuseputro P, Anderson GM, Alter DA, Laupacis A, et al. Revisiting Rose: strategies for reducing coronary heart disease. BMJ. 2006;332:659–662
   • CrossRef
10. Murray CJL, Lauer JA, Hutubessy RCW, Niessen L, Tomijima N, Rodgers A, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet. 2003;361:717–725
    • Abstract
    • Full Text
    • Full-Text PDF (222 KB)
    • CrossRef
11. Jackson R, Barham P, Bills J, Birch T, McLennan L, MacMahon S, et al. Management of raised blood pressure in New Zealand: a discussion document. BMJ. 1993;307:107–110
    • MEDLINE
    • CrossRef
12. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, The Stroke Association. JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl 5):v1–52.
13. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239
    • CrossRef
14. New Zealand Guidelines Group. The assessment and management of cardiovascular risk. Wellington: New Zealand guidelines group, 2003 (available at http://www.nzgg.org.nz/guidelines/0035/CVD_Risk_Full.pdf; accessed July 2008).
15. Tonkin A, Barter P, Best J, Boyden A, Furler J, Hossack K, et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Position statement on lipid management—2005. Heart Lung Circ. 2005;14:275–291
    • Full Text
    • Full-Text PDF (464 KB)
    • CrossRef
16. Australian Government Department of Health and Ageing. Pbs-eligibility criteria for lipid-lowering drugs. Canberra: DHA, 2006 (available at http://www.health.gov.au/internet/main/publishing.nsf/content/lipid_eligibilitycriteria.htm; accessed July 2008).
17. Chen L, Rogers SL, Colagiuri S, Cadilhac DA, Mathew TH, Boyden AN, et al. How do the Australian guidelines for lipid-lowering drugs perform in practice? Cardiovascular disease risk in the AusDiab study 1999–2000. Med J Aust. 2008;189:319–322
18. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121:293–298
    • MEDLINE
    • CrossRef
19. Forge BH, Briganti EM. Lipid lowering and coronary heart disease risk: how appropriate are the national guidelines?. Med J Aust. 2001;175:471–475
    • MEDLINE
20. Bett JH, Tonkin AM, Thompson PL, Aroney CN. Failure of current public educational campaigns to impact on the initial response of patients with possible heart attack. Int Med J. 2005;35:279–282
21. Clark AM, Hartling L, Vandermeer B, McAlister FA. Meta-analysis: secondary prevention programs for patients with coronary artery disease. Ann Intern Med. 2005;143:659–672
22. Daugherty SL, Ho PM, Spertus JA, Jones PG, Bach RG, Krumholz HM, et al. Association of early follow-up after acute myocardial infarction with higher rates of medication use. Arch Intern Med. 2008;168:485–491
    • CrossRef
23. Chew DP, Amerena J, Coverdale S, Rankin J, Astley C, Brieger D. Current management of acute coronary syndromes in Australia: observations from the acute coronary syndromes prospective audit. Intern Med J. 2007;37:741–748
24. Reid C, Nelson MR, Shiel L, Chew D, Connor G, DeLooze F. Australians at risk: management of cardiovascular risk factors in the REACH registry. Heart Lung Circ. 2008;17:114–118
    • Abstract
    • Full Text
    • Full-Text PDF (174 KB)
    • CrossRef
25. Wald N, Law M. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419–1424
    • CrossRef
26. Choudhry NK, Patrick AR, Antman EM, Avorn J, Shrank WH. Cost-effectiveness of providing full drug coverage to increase medication adherence in post myocardial infarction medicare beneficiaries. Circulation. 2008;117:1261–1268
    • CrossRef
27. Britt H, Miller GC, Charles J, Bayram C, Pan Y, Henderson J, Valenti L, O’Halloran J, Harrison C, Fahridin S. General practice activity in Australia 2006–2007. General practice series no. 21. Cat. no. GEP 21. Canberra: Australian Institute of Health and Welfare, 2008.
28. Department of Health, United Kingdom. Economic modelling of vascular checks. London: Department of Health, UK, 2008 (available at http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_085869; accessed December 2008).
29. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008;336:1475–1482
    • CrossRef
30. Carter R, Rankin B. Economic assessment of the NHFA proposal of a national CHD initiative in general practice. NHFA Research Report, December 2006.